827 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Downtrend
Article Searches
Intercept Reports Positive Top-Line Data for NASH, Shares Up http://www.zacks.com/stock/news/355517/intercept-reports-positive-top-line-data-for-nash-shares-up?cid=CS-ZC-FT-355517 Feb 20, 2019 - Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10. ... http://www.gurufocus.com/news/819032/merck--co-inc-mrk-chairman-president--ceo-kenneth-c-frazier-sold-109-million-of-shares Feb 19, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10.9 million of Shares, Stocks: MRK, release date:Feb 19, 2019
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster https://www.fool.com/investing/2019/02/19/pfizers-forgotten-cancer-pill-is-about-to-become-i.aspx?source=iedfolrf0000001 Feb 19, 2019 - A drug that disappointed in 2018 will get an unexpected dance at the big ball.
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer http://www.zacks.com/stock/news/355193/merck-gets-priority-review-for-keytruda-combo-in-kidney-cancer?cid=CS-ZC-FT-355193 Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-354853 Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/354603/astrazenecas-azn-q4-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-354603 Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Top Research Reports for ExxonMobil, Merck & Danaher http://www.zacks.com/research-daily/213347/top-research-reports-for-exxonmobil-merck-danaher?cid=CS-ZC-FT-213347 Feb 13, 2019 - Top Research Reports for ExxonMobil, Merck & Danaher
Bristol-Myers' Sprycel Gets European Nod for Label Expansion http://www.zacks.com/stock/news/354050/bristol-myers-sprycel-gets-european-nod-for-label-expansion?cid=CS-ZC-FT-354050 Feb 12, 2019 - Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion http://www.zacks.com/stock/news/354019/seattle-genetics-adcetris-gets-ec-nod-for-label-expansion?cid=CS-ZC-FT-354019 Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review http://www.zacks.com/stock/news/353912/pfizer-sbla-for-kidney-cancer-drug-combo-gets-priority-review?cid=CS-ZC-FT-353912 Feb 12, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.

Pages: 1...345678910111213...83

<<<Page 8>